Minerva Surgical

Minerva Surgical EV/FCF

EV/FCF (Enterprise Value to Free Cash Flow) of Minerva Surgical (UTRS) as of Nov 2, 2026.

EV/FCF

-0.00

YoY

-100.00%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Minerva Surgical is 2023 -0.00 . EV/FCF (Enterprise Value to Free Cash Flow) of Minerva Surgical was 2022 -0.92 . It decreases by -100.00% higher compared to the previous year.

The Minerva Surgical EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-2.44 USD
Jan 1, 2020
-6.30 USD
Jan 1, 2021
0.06 USD
Jan 1, 2022
-0.92 USD
Jan 1, 2023
-0.00 USD
The Minerva Surgical EV/FCF history
YEAREV/FCFYoY
-0.00-100.00%
-0.92-1,682.78%
0.06-100.92%
-6.30+158.20%
-2.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Minerva Surgical Stock analysis

What does Minerva Surgical do? Minerva Surgical, Inc. generates revenue through the commercialization of minimally invasive uterine healthcare solutions designed to treat abnormal uterine bleeding without necessitating hysterectomies. The company offers a suite of products targeting structural and non-structural causes of AUB, which are utilized by OB/GYNs in hospitals, ambulatory surgical centers, and physician offices. These devices address drawbacks of alternative treatments while preserving the uterus, appealing to healthcare providers seeking effective, non-invasive options for women's health. The firm's product line includes commercially available devices for minimally invasive alternatives to hysterectomy, specifically targeting the most common causes of AUB across various uterine anatomies. OB/GYNs across multiple medical settings purchase these solutions, leveraging their ability to address treatment limitations while avoiding unnecessary surgical interventions. The company's focus on preserving the uterus through non-hysterectomy methods differentiates its offerings in the women's health technology market. Minerva Surgical's revenue model relies on sales of its medical devices to healthcare providers, particularly OB/GYNs, who integrate the products into their treatment protocols for patients with abnormal uterine bleeding. The company's solutions are positioned as alternatives to traditional hysterectomy procedures, targeting a significant unmet need in women's healthcare. This approach allows the firm to capture market share by addressing both clinical and patient preference demands for less invasive care options. Minerva Surgical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Minerva Surgical stock

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Minerva Surgical since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Minerva Surgical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Minerva Surgical

All Key Metrics — Minerva Surgical